NCM
INSY

New Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

New Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-296
Closed -$3K – 155
2018
Q3 		$3K Buy
+296
New +$2.36K ﹤0.01% 143

Other funds holding INSY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

New Capital Management's INSY Position: Q4 2018 in Review

New Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2018, closing a stake of 296 shares — an estimated $3K sold.

New Capital Management first reported a position in INSY in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2018.

  • New Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • New Capital Management sold 296 Insys Therapeutics, Inc. shares in Q4 2018, an estimated $3K.
  • New Capital Management first reported a position in Insys Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • New Capital Management's Insys Therapeutics, Inc. position peaked at $3K in Q3 2018.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2018.

Based on New Capital Management's 13F filing for Q4 2018, filed 18 Jan 2019.